Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma

Overview of attention for article published in Frontiers in immunology, October 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

So far, Altmetric has seen 11 X posts from 9 X users, with an upper bound of 4,080 followers.

Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma #lymphoma #lymsm https://t.co/FeeoNA5Wzf

Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma #lymphoma #lymsm https://t.co/Nj8rDvaG6M

RT @tweet_Javi: Congratulations to @pompe_genyo @genyo_pts @FIBAO and sopecially #PacoMartinLab for yet another piece of evidence backing…

RT @tweet_Javi: Congratulations to @pompe_genyo @genyo_pts @FIBAO and sopecially #PacoMartinLab for yet another piece of evidence backing…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 7 additional X posts.